10-12 September 2018 //  Lancaster Royal Hotel, London


Sandra van Wetering

Dr Sandra van Wetering


Sandra van Wetering is an expert in the development and manufacturing of cell-based products, and has in-depth knowledge  the regulatory strategies and processes involved in development of such products, in the context of the relevant EMA/FDA regulatory framework for Advanced Therapeutic Medical Products (ATMP's) and associated GMP guidelines. She holds a PhD in immunology and also has strong knowledge of clinical development and execution of clinical operations, in particular in immunotherapy. She has been working for over 9 years as the COO of DCPrime, a clinical stage company that develops off-the-shelf dendritic cell-based vaccines for a broad range of cancer types, based on its unique, proprietary technology platform, DCOne. With her extensive experience in pharmaceutical CMC development, ranging from the pre-clinical stage up to Phase-II clinical trials, she is responsible for all operational activities related to the company’s strategy in product development, manufacturing, regulatory and clinical activities, from proof of principle to approved DCOne-based therapeutic products (US/EU). 


2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad